| Literature DB >> 20040573 |
Sylvia Steininger1, Fred Ahne, Klaudia Winkler, Anja Kleinschmidt, Friederike Eckardt-Schupp, Simone Moertl.
Abstract
The Mre11/Rad50/Xrs2 (MRX) complex in Saccharomyces cerevisiae has well-characterized functions in DNA double-strand break processing, checkpoint activation, telomere length maintenance and meiosis. In this study, we demonstrate an involvement of the complex in the base excision repair (BER) pathway. We studied the repair of methyl-methanesulfonate-induced heat-labile sites in chromosomal DNA in vivo and the in vitro BER capacity for the repair of uracil- and 8-oxoG-containing oligonucleotides in MRX-deficient cells. Both approaches show a clear BER deficiency for the xrs2 mutant as compared to wildtype cells. The in vitro analyses revealed that both subpathways, long-patch and short-patch BER, are affected and that all components of the MRX complex are similarly important for the new function in BER. The investigation of the epistatic relationship of XRS2 to other BER genes suggests a role of the MRX complex downstream of the AP-lyases Ntg1 and Ntg2. Analysis of individual steps in BER showed that base recognition and strand incision are not affected by the MRX complex. Reduced gap-filling activity and the missing effect of aphidicoline treatment, an inhibitor for polymerases, on the BER efficiency indicate an involvement of the MRX complex in providing efficient polymerase activity.Entities:
Mesh:
Substances:
Year: 2009 PMID: 20040573 PMCID: PMC2847237 DOI: 10.1093/nar/gkp1175
Source DB: PubMed Journal: Nucleic Acids Res ISSN: 0305-1048 Impact factor: 16.971
Saccharomyces cerevisiae strains used in this study
| Strain | Genotype | Reference |
|---|---|---|
| MKP-0 | BA. Kunz | |
| MKP-0 | Derivative of MKP-0 with | ( |
| MKP-0 | Derivative of MKP-0 | ( |
| MKP-0 | Derivative of MKP-0 | ( |
| MKP-0 | Derivative of MKP-0 with | This study |
| MKP-0 | Derivative of MKP-0 with | This study |
| MKP-0 | Derivative of MKP-0 with | This study |
| MKP-0 | Derivative of MKP-0 with | This study |
| MKP-0 | Derivative of MKP-0 with | This study |
| MKP-0 | Derivative of MKP-0 with | This study |
| MKP-0 | Derivative of MKP-0 with | ( |
| MKP-0 | Derivative of MKP-0 with | ( |
| BY4741 | Euroscarf | |
| BY4741 | Euroscarf |
Figure 1.Sensitivity to base-damaging agents and mutation frequencies. (A, B) Sensitivity of the xrs2 deletion mutant to MMS and H2O2 compared to MKP-0 wildtype and the rad52 deletion mutant. Survival was plotted as the ratio of colonies obtained after treatment versus colonies obtained without treatment. (C, D) Induced mutation frequencies of BY4741 wildtype and its isogenic xrs2 deletion mutant after MMS and H2O2 treatment shown as canavanine-resistant (CanR) mutants per 107 survivors. Results are an average of three independent experiments ± SD.
Figure 2.Analysis of the repair of heat-labile sites. (A) Induction of chromosomal degradation in wildtype and the xrs2 mutant visualized by pulsed-field gel electrophoresis. Cells were treated for 0, 15 and 30 min with 0.1% MMS. During preparation of chromosomal DNA, the incubation with proteinase K was carried out at 32°C (heat-labile sites remain stable) as well as 55°C (heat-labile sites are converted into DSB). (B) Analysis of chromosomal degradation (proteinase K incubation at 55°C) immediately after treatment for 0, 20 and 40 min with 0.1% MMS as well as after 23 h incubation of the cells under LHR conditions. (C) Residual DNA fragmentation plotted against the time of MMS treatment. The degree of residual chromosomal degradation was quantified using the software program Geltool and is shown as profile value (pv). Linear equations are calculated from regression lines (dashed lines). One representative experiment is shown. (D) Slope of regression lines obtained from residual chromosomal degradations from the xrs2 and rad52 mutant relative to wildtype. Mean values from three independent experiments for the xrs2 mutant and for wildtype are shown. The rad52 mutant was analyzed once.
Figure 3.In vitro analysis of short-patch and long-patch BER with whole-cell extracts from wildtype cells and from the xrs2 mutant. (A) Principle of the in vitro assay (X = uracil or 8-oxoG). Labeled repair products are generated by BER activity of whole cell extracts. (B, C) Repair capacities for the repair of the uracil-containing oligonucleotide (B) and the 8-oxoG-containing oligonucleotide (C) of cell extracts obtained from wildtype cells and from the xrs2 mutant. The number below the images indicates the relative intensity of the corresponding band relative to the strongest band in that line. (D) Relative BER activity of the xrs2 mutant after a 20-min repair time. The diagram shows the average of three independent experiments using the uracil-containing oligonucleotide; the results for the 8-oxoG-containing substrate were obtained from one experiment. (E) Analysis of the BER capacity in cell extracts from the rad52 mutant in comparison to cell extracts from wildtype cells and the xrs2 mutant using the uracil-containing substrate. One representative experiment out of three is shown. nd., not determined.
Figure 4.MMS sensitivity and BER capacity of MRX-deficient cells and mutants carrying truncated versions of the Xrs2 protein. (A) Analysis of the MMS sensitivity. Shown are serial dilutions of cells on plates containing MMS as indicated. (B) Repair capacity of cell extracts obtained from the mre11, the rad50 mutant and from strains expressing truncated versions of XRS2 compared to wildtype and the xrs2 deletion mutant. The numbers below the images indicate the relative intensity of the corresponding band relative to the strongest band in that line. One of three independent experiments is shown.
Figure 5.Epistatic relationship of XRS2 to other BER genes. (A, B) Analysis of MMS sensitivity. Shown are serial dilutions of cells on plates containing MMS as indicated. (C) Repair capacity for the repair of the uracil-containing oligonucleotide of cell extracts obtained from the apn1 and the apn1xrs2 mutant compared to cell extracts from wildtype cells and from the xrs2 single mutant. (D) Repair capacity for the repair of the uracil-containing oligonucleotide of cell extracts derived from the ntg1ntg2 double mutants and ntg1ntg2xrs2 triple mutant compared to cell extracts derived from wildtype cells and from the xrs2 single mutant. In each case, one representative experiment out of three is shown. (E) Proposed model for the allocation of XRS2 to the AP-lyase-mediated repair pathway. The phenotypes of the apn1 and xrs2 single mutants are combined in the apn1xrs2 double mutant; otherwise, the effect of xrs2 is suppressed in the ntg1ntg2 mutant. These findings assign the MRX complex downstream of the AP-lyases where short-patch and long-patch repair products can be synthesized.
Figure 6.Analysis of individual steps in the BER process after deletion of XRS2. (A) Incision assay using the uracil-containing oligonucleotide. Generation of an AP site and incision activity can be monitored through the appearance of cut products of the labeled substrate. (B) Incision assay with whole-cell extracts derived from wildtype cells and form the xrs2 (left part of image) and the apn1 (middle part of image) mutant. Stability of the phosphodiester bond was demonstrated by using an UDG-treated (Uracil-DNA-Glycosylase) substrate. The successful generation of AP-sites after UDG-treatment was shown by hydrolyzing the phosphodiester bond under alkaline conditions (right part of image). (C) Four-nucleotide gap-filling assay; gap-filling activity is visible through the extension of the 5′-labeled substrate. (D) Gap-filling activity of cell extracts derived from the xrs2 mutant compared to cell extracts from wildtype cells. (E) In vitro BER assay of whole-cell extracts from wildtype cells and from the xrs2 mutant preincubated with 2 µg/ml aphidicoline for 30 min. In each case, one representative experiment out of three is shown.